Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
Metastatic gastric cancer (GC) with limited therapeutic options has a poor prognosis, and therefore, major therapeutic advances are needed. Comprehensive genomic characterization has improved understanding of GC but a great majority of genomic profiling has not been effectively translated to the cli...
Main Authors: | Jang Ho Cho, Jeeyun Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Sungkyunkwan University School of Medi
2017-12-01
|
Series: | Precision and Future Medicine |
Subjects: | |
Online Access: | http://www.pfmjournal.org/upload/pdf/pfm-2017-00177.pdf |
Similar Items
-
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01) -
Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01) -
Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2019-01-01) -
Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
by: Yuan Gao, et al.
Published: (2017-07-01) -
Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for
Non-small Cell Lung Cancer
by: Cheng LIN, et al.
Published: (2014-10-01)